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The recently discovered 150-cavity in the active site of group-1 influenza A neuraminidase 
(NA) proteins provides a target for rational structure-based drug development to counter the 
increasing frequency of antiviral resistance in influenza. Surprisingly, the 2009 H1N1 pandemic 
virus (09N1) neuramidase was crystalized without the 150-cavity characteristic of group-1 
NAs. Here we demonstrate, through a total sum of 1.6 µs of biophysical simulations, that 09N1 
NA exists in solution preferentially with an open 150-cavity. Comparison with simulations 
using avian N1, human N2 and 09N1 with a I149V mutation and an extensive bioinformatics 
analysis suggests that the conservation of a key salt bridge is crucial in the stabilization of the 
150-cavity across both subtypes. This result provides an atomic-level structural understanding 
of the recent finding that antiviral compounds designed to take advantage of contacts in the 
150-cavity can inactivate both 2009 H1N1 pandemic and avian H5N1 viruses. 
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Understanding the structural dynamics of the influenza glyco-proteins has been a long-standing goal because of their direct impact on public health. The two major influenza glycopro-
teins, hemagglutinin (HA) and neuraminidase (NA), control entry 
and exit of the viral particles from the host cell, respectively. HA 
binds to sialic acid surface receptors on the host cell, whereas NA 
cleaves the terminal sialic acid receptor linkage, facilitating viral 
shedding. The nine NA alleles have been divided into two groups 
based on phylogenetic analysis (group-1: N1, N4, N5, N8; group-
2: N2, N3, N6, N7, N9)1. During the last century, influenza viruses 
carrying N1 (H1N1) or N2 (H2N2, H3N2) alleles have circulated 
in humans, first as pandemic strains and then, after subsequent 
adaptation to humans, as seasonal epidemic strains. Thus, a better 
understanding of the structural dynamics of N1 and N2 is particu-
larly relevant for antiviral design.
Oseltamivir (Tamiflu) and zanamivir (Relenza), which target 
the NA, are currently the only antivirals approved by the FDA for 
the prophylaxis and treatment of influenza. These drugs, developed 
against available group-2 NA structures, represent some of the first 
successful rational structure-based drug development efforts2. The 
crystal structures of group-1 NAs revealed a never-before-seen 150-
cavity adjacent to the sialic-acid-binding site1. It has been hypoth-
esized, and very recently shown3, that targeting the 150-cavity may 
allow the development of new antivirals with increased specificity 
and potency against group-1 enzymes. The increasing frequency of 
oseltamivir resistance in pre-2009 seasonal H1N1 viruses4 and the 
occasional observation of oseltamivir resistance among 2009 H1N1 
pandemic viruses motivates new antiviral development. Having 
additional antivirals in our treatment arsenal would be advanta-
geous, and potentially critical, if a highly virulent strain, for exam-
ple, H5N1, evolved the ability to undergo rapid transmission among 
humans or if the already highly transmissible 2009 H1N1 pandemic 
virus was to evolve resistance to existing antiviral drugs.
Recently, it was revealed that the structure of the 2009 pandemic 
H1N1 NA lacked a 150-cavity, despite being a group-1 NA5. This 
surprising finding suggested that the 2009 pandemic N1 protein 
was structurally more similar to the group-2 NAs than to the group-
1 NAs. Based on alignments of sequences representing all available 
NA crystal structures, highly conserved residues in the 150-loop and 
the 430-loop (residues 147–152 and 429–433, respectively, in N2 
numbering) were hypothesized to functionally determine the struc-
ture of the 150-cavity5. In particular, I149 was found to be common 
between the 2009 pandemic N1 and group-2 NAs, whereas V149 
was conserved among the other group-1 NAs. In the two solved N2 
structures, which have somewhat atypical sequences, a salt bridge 
between D147 and H150 appeared to prevent the opening of the 
150-loop, despite the presence of V149.
Here we test the hypothesis that position 149 is critical for deter-
mining the open or closed status of the 150-cavity. Our alternative 
hypothesis is that cavity status is plastic in the absence of a D147-
H150 salt bridge, being dependent on loop conformations that are 
themselves flexible. Earlier computational studies of N1 from avian 
H5N1 showed that this isolate exhibited remarkable flexibility in the 
150-loop6. The same avian N1 was also reported to contain a closed 
150-loop under certain crystallization conditions1 and additionally 
shown to be able to switch to a closed loop position during a molecu-
lar dynamics (MD) simulation initiated from the co-crystallized osel-
tamivir-bound open-150-loop configuration6. The understanding 
that emerged was that the avian N1 was able to adopt a wide range of 
configurations in the 150-loop region, favouring an open conforma-
tion of the 150-cavity overall. We examined the flexibility of the 150-
cavity area in the 09N1 crystal structure through molecular dynamics 
simulations using 09N1 and other available structures of N1 and N2 
alleles derived from human clinical isolates. In combination with the 
simulations, an extensive bioinformatics analysis for these alleles in 
the 150- and 430-loop regions offers new clues as to the controlling 
features of 150-cavity formation in these critical enzymes. Ultimately, 
we found that a key salt bridge appears to control the 150-cavity for-
mation in both group-1 and group-2 enzymes, both of which are able 
to adopt flexible loop conformations in this critical region. We pro-
pose that this new structural understanding can be related to antiviral 
design for any of the influenza NA enzymes.
Results
Molecular dynamics simulations. To probe the effect of sequence 
on the atomic-level structure and dynamics of these critical enzymes, 
we performed four separate 100-ns molecular dynamics simulations 
for four tetrameric NA enzymes: (1) A/California/04/2009, an 
H1N1 virus isolated early in the 2009 pandemic (09N1, Protein 
Data Bank (PDB) accession code: 3NSS)5. We note that the N1 allele 
in the pandemic strain had recently evolved from an Eurasian-
lineage H1N1 swine virus7. (2) A mutant N1 that we engineered 
in silico from A/California/04/2009 by substituting Val for Ile at 
position 149 (09N1_I149V). (3) A/Vietnam/1203/04, an avian-
derived H5N1 virus isolated from a human (VN04N1, PDB 
accession code: 2HTY)1. (4) A/Tokyo/3/67, a seasonal human 
H2N2 virus (N2, PDB accession code: 1NN2)8. We note that the 
I149V mutation in A/Tokyo/3/67 is atypical for a human N2 allele 
(Table 1; Supplementary Table S1).
The homotetramer configuration of NA allows us to take advan-
tage of multicopy simulation sampling9, amounting to the equiva-
lent of nearly half a microsecond (400 ns) of sampling for each NA 
monomer, while accounting for realistic neighbouring subunit 
effects within the structural dynamics. Alpha-carbon root mean 
square deviation (RMSD) plots for the tetramer systems and indi-
vidual monomer chains exhibit stability over 100 ns, and there 
is good agreement between experimental and simulation-derived 
B-factors (Supplementary Figs S1–S3).
Pandemic 2009 H1N1 exhibits open 150-cavity. Our simulations 
reveal that the pandemic 09N1 NA is able to adopt open 150-cavity 
conformations in normal solution dynamics, and, in contrast to the 
crystal structure, it appears to favour an open 150-cavity conforma-
tion overall (Fig. 1; Table 1). In the simulations of 09N1, the 150-
loop transitions to an open configuration by 50 ns in all chains of 
the tetramer (Supplementary Fig. S4). As a reference for open- and 
closed-loop structures, the PDB accession codes 2HTY and 2HU4 
were utilized, respectively. The open 150-cavity crystal structure 
(2HTY with hydrogen atoms added) exhibits a 150-cavity volume of 
36 Å3 as computed by POVME10 (Supplementary Table S3). Closed 
150-cavity crystal structures (1NN2, 2HU4, 3NSS with hydrogen 
atoms added) were used as references and uniformly exhibit a vol-
ume of 0 Å3. To quantify the extent to which structures within the 
dynamical ensemble adopt either a closed or open 150-cavity con-
formation, a time series of the pocket volume was computed over 
the course of the trajectory (Fig. 2a; Supplementary Fig. S5). Struc-
tures were subsequently classified as open or closed based on 150-
cavity volume, that is, cavities with volumes greater than or equal 
to 18 Å3, or at least half of the crystal structure open-cavity volume, 
are considered ‘open.’ Through this method, we determined that the 
09N1 system adopts an open 150-cavity during the majority of the 
simulation (60.8%, Table 2). We note that longer simulation times 
may further increase the percentage of 09N1 in the open confor-
mation, overcoming the structural bias due to the simulation being 
initiated with a closed 150-cavity.
RMSD-based clustering of the 150-loop residues enables an 
atomic-level population-based structural analysis. Although the 
most populated cluster, that is, the cluster that comprises at least 
33% of the sampled ensemble, has a closed 150-loop configuration, 
structures within the next two most populated clusters adopt open 
150-cavity configurations (Fig. 1; Supplementary Table S2). Figure 2 
clearly shows that the second most dominant cluster from the 09N1 
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simulations has an open 150-loop, highly similar to the open 150-
loop of VN04N1. By comparison, the VN04N1 150-cavity is con-
sistently open throughout the simulations, being present for 93.4% 
of the trajectory (Figs 1 and 2b; Table 1; Supplementary Fig. S6). 
The formation of a stable and open 150-cavity in 09N1 indicates 
that the structural dynamics of the recent pandemic strain appear 
X-ray
N2
VN04N1
09N1
09N1
l149V
MD Cl-1 MD Cl-2 MD Cl-3
Figure 1 | Solvent accessible surface area of NA-binding site. The solvent accessible surface area of the NA-binding site is shown, as computed by the 
MSMS30 program, for the X-ray structure, and top three most dominant central member cluster structures (population percentages indicated in white text 
for each cluster), shown for A/Tokyo/3/67 (N2), A/Vietnam/1203/04 (VN04N1), A/California/04/2009 (09N1) and the 09N1_I149V mutant strain. 
The open 150-cavity, where present, is outlined with a dotted circle.
Table 1 | Variation in the 150- and 430-loops of N1 and N2 NA alleles of avian, swine and human influenza viruses.
Host N1 and N2 alleles N 150-loop 430-loop
147 149 150 430 431 432
Swine N1 N1 swine H1N1 classic lineage consensus 158 G V K Q P K
N1 swine H1N1 Eurasian lineage consensus 165 G I/V K R P K
Human N1 N1 human H1N1 2009 pandemic consensus and 
A/California/04/2009
1,806 G I K R P K
N1 human H1N1 seasonal 2007–2009 consensus 1,809 G V K L P R
N1 human H1N1 seasonal 1950–2007 consensus G V K R P R
N1 human H1N1 seasonal 1930–40s consensus G V K R P K
N1 human H1N1 1918 pandemic G V K Q P K
Avian N1 N1 avian consensus and A/Vietnam/1203/2004 2,141 G V K R P K
Human N2 N2 human H3N2 seasonal mid-2000s-present 
consensus
1,727 N/D V R R K E
N2 human H3N2 seasonal 1990-mid 2000s consensus D V H R K Q/E
N2 human H3N2 seasonal 1970–80s consensus D I H R E Q
N2 human H3N2 1968 pandemic (NA of human  
H2N2 origin)
D I H R K Q
N2 human H2N2 seasonal A/Tokyo/3/1967  
(atypical 149V)
D V H R K Q
N2 human H2N2 seasonal 1960s consensus 88 D I H R Q/K Q
N2 human H2N2 1957 pandemic (NA of avian origin) G I H R P Q
Avian N2 N2 avian polymorphisms seen since the mid-1990s 1,743 G T/A/S H R P K/Q
N2 avian consensus G I H R P Q
Consensus sequences contain amino acids at a frequency of at least 80%. Sequences in bold font correspond to structures simulated in this paper. Table entries are single-letter amino acid codes .
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to be more similar to the classic group-1 isolates than to the group-
2 isolates, in contrast to what the static crystal structure suggests. 
This finding provides an atomic-level structural understanding of 
how antiviral compounds designed to take advantage of contacts in 
the 150-cavity can be active against both the 2009 H1N1 and 2004 
Vietnam H5N1 isolates, as very recently shown in ref. 3.
150-Cavity formation controlled by a conserved salt bridge. The 
dynamics of the N2 strain reveal that a key salt bridge between 
conserved residues D147 and H150 controls the formation of the 
150-cavity in N2. This ionic contact locks I149 in the space of the 
150-cavity (Fig. 3), as suggested in ref. 5. However, in each chain of 
the N2 tetramer simulation, this salt bridge intermittently breaks 
and then reforms; in chain C, at 60 ns the contact is lost again, after 
which the open 150-cavity forms, and contact to the 430-loop is lost 
(Fig. 2c; Supplementary Fig. S7). The loss of the D147-H150 salt 
bridge allows the 150-loop to move to the open position, even wider 
than the VN04N1 open 150-loop structure (Fig. 2). RMSD-based 
clustering of the 150-loop indicates that while both the first and sec-
ond most dominant configurations remain closed, the third most 
dominant configuration, representing 6.8% of the trajectory, exhib-
its an open 150-cavity (Fig. 1). Volumetric calculations of the 150-
cavity confirm that the open-cavity conformation is present in 10% 
of the simulation and has a volume of 284 Å3. For the remainder of 
the simulation, the salt bridge does not reform, and the wide-open 
150-cavity therefore persists in one chain of the N2 tetramer.
The spontaneous loss of this key contact under ‘physiologically 
relevant’ simulation conditions provides a clear atomic-level model 
for 150-cavity formation in the N2 clinical isolate. The loss of the 
salt bridge reduces the rigidity of the 150-loop, enabling the loop to 
sample more open conformations. Contacts with the neighbouring 
430-loop are simultaneously lost, and significant expansions of both 
the 150- and 430-cavities occur (Figs 1, 2C and 3; Supplementary 
Table S3 and Supplementary Fig. S8). Although the open 150-loop 
is energetically accessible in the N2 structures, its low population 
during the simulation makes it unlikely that this open 150-cavity 
would appear in X-ray crystallography experiments. Such a cavity 
would be able to accommodate compounds targeting the 150-cav-
ity, albeit with a lower affinity, as very recently shown in ref. 3. In 
all the N1 proteins, D147 is replaced with an uncharged G147, and 
therefore no salt bridge is present to lock I/V149 in the 150-cavity 
space. This may explain why an open 150-cavity is characteristically 
observed in crystals, even in 09N1, which is able to adopt a stable 
open 150-cavity conformation. It also underscores the importance 
of considering solution-phase dynamics for these enzymes and not 
only crystallographic information, which is generally only able to 
provide one low-energy snapshot of the dynamic protein complex 
under crystalline conditions.
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Figure 2 | Time series analysis of 150-cavity volume and width for 
a particular monomer in each of the simulated systems. on the left-
side y axis, the volume of the 150-cavity is computed over the course of 
simulation. The distance between alpha-carbon of residue 431 (PRo in  
a, b, d; LYS in c) and the closest side-chain carbon of residue 149 (Val149 
panels b, c, d; ILE in a) is computed and shown in red and the right-side 
y axis. The black and red dotted lines correspond to the open crystal 
structure (2HTY) volume and distance, respectively; whereas the  
black dashed and red solid lines correspond to the closed crystal  
structure (2Hu4) volume and distance, respectively. The systems  
shown are A/Tokyo/3/67 (N2), A/Vietnam/1203/04 (VN04N1),  
A/California/04/2009 (09N1) and the 09N1_I149V mutant strain.
Table 2 | Population analysis based on open or closed 150-cavity.
System (crystal structure) Crystal structure state of 
150-cavity
147.149,150…431 Total open (%) Total closed (%)
N2 (1nn2) Closed D.VH…K 202 (10.1%) 1,798 (89.9%)
VN04N1 (2hty) open G.VK…P 1,867 (93.4 %) 133 (6.6%)
09N1 (3 nss) Closed G.IK…P 1,215 (60.8 %) 785 (39.2%)
09N1_I149 V (3 nss*) Closed G.VK…P 742 (37.1 %) 1,258 (62.9%)
*3nss accession code with the I149V mutation introduced in silico.
a b
Figure 3 | Structural variation in N1 and N2 clinical isolates. (a) The 
150- and 430-loop structures are shown for 09N1 crystal structure 
(purple), 09N1 second most dominant molecular dynamics (MD) 
cluster representative structure (green backbone) and VN04N1 crystal 
structure (orange), indicating that the pandemic N1 adopts an open 
150-loop conformation. Gly147, Ile149, Lys150 and Pro431 are shown in 
stick representation. (b) N2 150- and 430-loops from crystal and most 
dominant cluster representative structures are shown in blue, and open 
VN04N1 crystal structure are shown in orange. The D147-H150 salt bridge 
spontaneously ruptures in chain C of N2, extending its initial contact from 
2.8 Å in crystal structure to 11.8 Å in the most dominant MD-generated 
cluster structure, revealing a wide-open 150-cavity.
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Among N1 alleles for which structures exist, the 2009 H1N1 
pandemic isolate uniquely contains an I149. Thus, Li et al.5 hypothe-
sized that the additional extension of the I149 side chain, compared 
with V149, may be a compensating factor in controlling the closed-
loop structure, despite strict conservation of all other residues in 
this area. Structurally, the longer side chain of I149 may facilitate 
van der Waals contacts to the neighbouring 430-loop, and shift the 
population to a more closed 150-loop state; a V149 mutation would 
facilitate loss of contact between the 150- and 430-loop, shifting the 
population to a more open 150-cavity state. To test this hypothesis, 
we created the 09N1_I149V mutant strain in silico and performed 
an identical 100 ns simulation. Our results indicate that the effect of 
this mutation on 150-cavity status varies due to 150-loop flexibility. 
The time series data indicate that the I149V mutation caused chain 
D to open almost immediately, chain C to open after 60 ns, chain A 
to open intermittently and had almost no effect on chain B (Supple-
mentary Fig. S9). Overall, the 09N1_I149V mutant is actually more 
closed, exhibiting the open 150-cavity less frequently, in only 37.1% 
of the simulation, compared with the normal 09N1 strain with the 
I149 present (Table 2, Fig. 2d; Supplementary Fig. S9). Moreover, 
only one of the three most dominant structures, cluster 2, presents 
the open 150-cavity, and thus, the V149 by itself cannot explain the 
behaviour of the 09N1_I149V.
Analysis of sequence conservation in the 150-loop region. To 
date, the evolutionary distribution of the 150-cavity among NA alle-
les has been inferred primarily from crystallographically resolved 
structures, which represent a limited subset of the genetic varia-
tion of NAs in nature. Based on those analyses, it seemed logical 
to attribute the occurrence of an open 150-cavity to having a V or 
I at position 149, and by extension, to membership, in the group-1 
or group-2 NAs, respectively, as shown in figure 3 of Li et al. Our 
dynamical analyses suggest that I/V149 is not as critical to 150-cavity 
status as the D147-H150 salt bridge, which warrants re-examination 
of the association of cavity status with NA group membership. We 
determined the distribution of genetic variation in the 150 and 450 
loops among all avian, human and swine N1 and N2 sequences that 
had been deposited in GenBank and Global Initiative on Sharing 
Avian Influenza Data (GISAID) as of 12 August 2010 using phylo-
genetic analysis to construct consensus sequences for each major 
clade (Supplementary Methods for methodological details).
Our phylogenetic analyses (Table 1) show that no single amino 
acid position in the 150- or 430-loops clearly differentiates the N1 
and N2 alleles, which are in group-1 and group-2, respectively. The 
D147-H150 salt bridge is not a defining characteristic of N2 alle-
les, as it is not present in avian viruses, which were the source of 
the N2 allele in the 1957 H2N2 human pandemic strain. Nor is the 
salt bridge found in human H3N2 viruses that have been circulat-
ing since 2008, due to fixation of a D147N mutation. Thus, neither 
the amino acid at position 149 nor the salt bridge is fixed characters 
that differentiate group 1 and group 2 NAs. Nor do they, at least 
by themselves, characterize viruses capable of infection of humans. 
Additional tests of our hypothesis require the acquisition of crystal 
structures of additional NA alleles, most critically, an N2 allele that 
contains both the D147-H150 salt bridge and I149.
Discussion
Our results highlight the importance of interpreting influenza NA 
sequence and structural data in light of the dynamical ensemble of 
conformations that are accessible to each NA protein. This work 
shows for the first time that both N1 and N2 clinical isolates exhibit 
flexibility in the 150-cavity neighbouring the conserved sialic-
acid-binding site. Although it remains possible that the open and 
closed conformation observed in crystal structures may be due to 
differences in crystallization conditions or procedures, our results 
indicate that the presence of the 150-cavity is not a strictly defining 
characteristic for group-1 or group-2 NA enzymes. Instead, it 
appears that both N1 and N2 enzymes are able to adopt an open 
150-cavity within their solution phase structural ensemble, in vari-
ous relative populations, which appear to be predominantly control-
led by the presence of the D147-H/R150 salt bridge. This suggests 
a new paradigm for the understanding of the presence of the 150-
cavity in both group-1 and group-2 NAs. The inherent flexibility 
of the 150- and 430-loops may have a role in full glycan receptor 
recognition, and in particular, with facilitating recognition events 
with the distal sugar residues of different glycan receptors. It is likely 
that the opening and closing of the 150-cavity is required for natu-
ral sialoglycan substrates to fit into the active site, given the bulky 
nature of these glycans.
This study additionally underscores the need to consider dynam-
ics in rationalizing the structure–function relationships of various 
antiviral–NA pairs. Ensemble-based drug discovery approaches11 
that account for full-receptor flexibility towards NAs that do not 
contain the D147-H150 salt bridge will likely present additional 
advances in the design of compounds that selectively target the 
150-cavity, opening the possibility for receptor-specific inhibitors. 
In closing, we note that whether the flexibility of the NA-binding 
site has an impact on receptor specificity, virus transmissibility or 
pathogenicity remains to be seen and will likely require a better 
understanding of HA receptor-binding domain dynamics for each 
of the NA/HA pairs found in humans12.
Methods
Simulation protocol. System setup was performed as follows for all simulated 
systems. Atomic coordinates were taken from 2HTY for A/Vietnam/1203/04 
(VN04N1)1, 3NSS for A/California/04/2009 (09N1)5 and 1NN2 for A/Aichi/3/67 
(N2)8. Protonation states for histidines and other titratable groups were deter-
mined at pH 6.5 by the PDB2PQR13 web server using PROPKA14 and manually 
verified. All crystallographically resolved water molecules and calcium ions were 
retained where possible and taken by homology from 2HTY if not present. The 
system was setup using the AMBER1115 program xLeap using the AMBER99SB 
force field16. Disulphide bonds were properly enforced using the CYX notation 
in AMBER. A 10–12 Å pad of TIP3P waters was added to solvate to each system. 
Neutralizing counter ions were added to each system. In order to mimic experi-
mental assay conditions, a 20 mM NaCl salt bath was introduced. System details 
and additional methodological information can be found in the Supplementary 
information.
N1 and N2 tetramer simulations were performed with a version of the PMEMD 
module from AMBER 11 that was custom tuned for these specific simulations and 
the NICS Cray XT4 and SDSC Trestles supercomputers by SDSC under the NSF’s 
TeraGrid Advanced User Support Program. The N1 and N2 apo tetramer com-
plexes were minimized and equilibrated as follows: in order to alleciate any steric 
clashes before performing molecular dynamics, the structures were minimized in 
a number of stages in which harmonic restraints of initially 5 kcal mol − 1 Å − 2 on all 
non-hydrogen protein atoms were slowly reduced over ~40,000 combined steepest 
descent and conjugate gradient minimization steps.
Following minimization, the system was linearly heated to 310 K in the canonical  
NVT ensemble (constant number of particles, N; constant volume, V; constant 
temperature, T) using a Langevin thermostat, with a collision frequency of 5.0 ps − 1, 
and harmonic restraints of 4 kcal mol − 1 Å − 2 on the backbone atoms. Then, a further 
three 250 ps long runs at 310 K were conducted in the NPT ensemble with the 
restraint force constant being reduced by 1 kcal mol − 1 Å − 2 each time and pressure 
controlled using a Berendsen barostat17 with a coupling constant of 1 ps and a 
target pressure of 1 atm. A final 250 ps of NPT dynamics was run at 310 K without 
restraints and a Langevin collision frequency of 2 ps − 1. Production runs were then 
made for 100 ns duration in the NVT ensemble at 310 K. As with the heating, the 
temperature was controlled with a Langevin thermostat (but with a 1.0 ps − 1 colli-
sion frequency). The time step used for all stages was 2 fs and all hydrogen atoms 
were constrained using the SHAKE algorithm18. Long-range electrostatics were 
included on every step using the Particle Mesh Ewald algorithm19 with a 4th order 
B-spline interpolation, a grid spacing of  < 1.0 Å, and a direct space cutoff of 8 Å. For 
all trajectories, the random number stream was seeded using the wall clock time in 
microseconds. The production trajectories for each monomer of the tetramer were 
extracted and concatenated to approximate 400 ns of monomer sampling.
RMSD clustering. RMSD clustering was performed as implemented in the 
rmsdmat2 and cluster2 programs of the GROMOS +  +  analysis software20. A total 
of 500 tetramer structures were collected by sampling at 200 ps intervals. Monomer 
structures were then concatenated together, yielding a total of 2,000 structures. 
Before clustering, external translational and rotational motions were removed by 
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minimizing the RMSD distance of the alpha-carbon atoms of the sampled structure 
to the equivalent atoms of the first frame of chain A. Using a 2.6 Å cutoff, clustering 
was then performed using the GROMOS +  +  clustering algorithm21 in Gromacs22 
on the alpha-carbon atoms of the 6-residue subset, 146–152, which comprise the 
150 loops. Each cluster contains a central structure, or ‘cluster representative mem-
ber,’ called the ‘centroid,’ whose RMSD is equidistant to all other cluster members. 
The cluster representative’s structural properties are considered characteristic of all 
cluster members. Cluster results are summarized in Table 2.
RMSD and B-factor calculations. B-factor calculations, as well as tetramer and 
monomer RMSD time series, were performed using the ptraj analysis tool in the 
AMBER 10 program suite23. Structures were sampled at 20 ps intervals. Before 
performing each calculation, external translational and rotational motions were 
removed by minimizing the RMSD distance of the alpha-carbon atoms to the 
equivalent atoms of the first frame of the trajectory. RMSD and B-factor values 
were calculated for alpha-carbon atoms.
09N1 RMSD 150-loop measurements. RMSD values were measured using 
a custom, hand-written script in the VMD TCL-TK console24. Structures were sam-
pled at 20 ps intervals. Sampled structures of each monomer were RMSD-aligned 
by alpha-carbon to the equivalent alpha-carbon atoms of the ‘reference’ structure: 
chain A of PDB ID 2HTY, open reference; or chain A of PDB ID 2HU4, closed 
reference. Following alignment, the RMSD of the 150 loop of each monomer was 
measured with respect to the 150 loop of each reference structure. The 150 loops 
were defined as residues 146–152 for the 09N1 monomers, as well as for the open 
and closed reference structures.
Interatomic distance measurements. The distance separating the salt bridge 
pair ASP147 and HIS150 was measured using a custom, hand-written script in the 
VMD TCL-TK console. Structures were sampled at 20 ps intervals. The distance 
between the two residues was defined as the distance separating centres of mass 
of the heavy atoms of the ASP147 carboxylate and the HIS 150 imidazole. The 
distance between residues 149 and 431 were measured for each step using a  
custom VMD script.
Neuraminidase volume population analysis. The numbers of open or closed 
150-cavity conformations out of a total of 2,000 snapshots were computed. Any 
instantaneous volume equal to or greater than half the volume of the crystal 
structure of canonical group-1 serovar (2HTY exhibits a total 150-cavity volume 
of 36 Å3) is considered to be ‘open’. Otherwise the 150-cavity is considered ‘closed’ 
(that is, when it exhibits  < 18 Å3). The volume of the 150-cavity was measured for 
each step by using POVME10; a pocket volume measuring algorithm. To measure 
the volume, we used a single inclusion sphere that encompassed the 150-cavity. The 
POVME algorithm neglected the volume occupied by NA atoms and not spatially 
contiguous with a point specified within the 150-cavity. By rotating 90° around the 
NA tetramer central axis, each of the other three 150-cavity sites were specified. 
The volume was thus measured for every snapshot of the simulation on all four 
chains of each NA.
Figures and plots. Matlab was used to generate all plots and molecular images 
were created using VMD24.
Consensus sequences. We downloaded all influenza A N1 and N2 gene sequenc-
es from humans, avians and swine that were  > 600 bp in length from GenBank 
and GISAID on 12 August 2010. We aligned sequences using ClustalX 2.0 (ref. 25) 
and constructed phylogenetic trees using MrBayes version 3.1.2 (ref. 26) using the 
GTR + I + gamma model, as suggested by jmodeltest version 0.1.1 (ref. 27) under 
the Akaike Information Criterion. All other MrBayes parameters were set to the 
default. We allowed MrBayes to run, sampling every 1,000 trees, until the Monte 
Carlo Markov chains converged as determined by Tracer software version 1.5 
(ref. 28). We discarded the burn-in as determined by Tracer. Similar results were 
obtained using the neighbour-joining routine of PAUP* 4.0b10 (ref. 29; results not 
shown). Consensus sequences containing amino acids found at a frequency of at 
least 80% were constructed for each major evolutionary clade. Results are shown, 
along with samples sizes, in Table 1. 
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